Korro Bio, Inc. (KRRO) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low16.3·High16.3
P/B Ratio
↓
2.44
↓-23% vs avg
5yr avg: 3.18
30Y Low0.4·High8.7
ROE
↓
-110.7%
↓+31% vs avg
5yr avg: -161.6%
30Y Low-365%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KRRO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Korro Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $125M | $75M | $340M | $73M | $49M | $1.1B | $1.1B | $541M | — | — |
| Enterprise Value | $147M | $97M | $329M | $-59642644 | $179M | $1.1B | $963M | $341M | — | — |
| P/E Ratio → | -1.07 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 19.62 | 11.77 | 149.54 | — | — | 81.08 | 30.75 | 18.68 | — | — |
| P/B Ratio | 2.44 | 1.46 | 2.12 | 0.43 | — | 8.72 | 5.91 | 3.23 | — | — |
| P/FCF | — | — | — | — | — | — | — | 16.31 | — | — |
| P/OCF | — | — | — | — | — | — | — | 15.80 | — | — |
P/E links to full P/E history page with 30-year chart
KRRO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.16 | 144.75 | — | — | 78.66 | 26.04 | 11.76 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 10.27 | — | — |
KRRO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Korro Bio, Inc. earns an operating margin of -1366.4%. Operating margins have expanded from -4047.1% to -1366.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -110.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.0% | 33.0% | 100.0% | — | — | 72.7% | 95.7% | 41.9% | — | — |
| Operating Margin | -1366.4% | -1366.4% | -4047.1% | — | — | -597.3% | -74.5% | -71.4% | — | — |
| Net Profit Margin | -1834.5% | -1834.5% | -3680.4% | — | — | -602.0% | -71.7% | -64.8% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.7% | -110.7% | -50.6% | -229.0% | -365.1% | -52.4% | -14.7% | -30.5% | — | — |
| ROA | -69.0% | -69.0% | -37.3% | -55.0% | -44.8% | -37.6% | -10.9% | -14.0% | -59.6% | -102.3% |
| ROIC | -58.8% | -58.8% | -73.9% | -186.5% | -69.2% | -109.7% | -113.9% | — | — | — |
| ROCE | -55.8% | -55.8% | -44.5% | -63.3% | -49.4% | -40.8% | -13.5% | -19.6% | -64.9% | -92.8% |
KRRO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $22M ($43M total debt minus $22M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | 0.28 | 0.20 | — | 0.35 | 0.24 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.42 | -0.07 | -0.78 | — | -0.26 | -0.91 | -1.20 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -6.04 | — | — |
| Interest Coverage | — | — | — | — | -499.98 | -109.83 | — | — | -179.83 | -115.30 |
KRRO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Korro Bio, Inc.'s current ratio of 6.90x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.87x to 6.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.90 | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 | 8.45 | 4.19 | 11.38 | 8.07 |
| Quick Ratio | 6.90 | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 | 8.45 | 4.19 | 11.38 | 8.07 |
| Cash Ratio | 6.30 | 6.30 | 8.43 | 8.53 | 6.42 | 11.44 | 8.27 | 4.12 | 11.18 | 8.06 |
| Asset Turnover | — | 0.06 | 0.01 | — | — | 0.08 | 0.14 | 0.13 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 55.33 | 272.58 | — | — | 3.74 | 3.36 | 10.15 | — | — |
KRRO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Korro Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 6.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $9M | $9M | $2M | $255174 | $4M | $645064 | $616890 | $627085 | $627085 |
Peer Comparison
Compare KRRO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KRROYou | $125M | -1.1 | — | — | 33.0% | -1366.4% | -110.7% | -58.8% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $311M | -1.8 | — | — | — | — | -198.1% | — | — |
 CRSP | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 PRME | $616M | -2.5 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 RCKT | $418M | -1.9 | — | — | — | — | -60.3% | -63.2% | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 ILMN | $22B | 26.2 | 20.1 | 23.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 PACB | $516M | -1.6 | — | — | 24.2% | -308.0% | -51.3% | -27.6% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See KRRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KRRO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KRRO vs BEAM
Side-by-side business, growth, and profitability comparison vs Beam Therapeutics Inc..
Start ComparisonKRRO — Frequently Asked Questions
Quick answers to the most common questions about buying KRRO stock.
What is Korro Bio, Inc.'s P/E ratio?
Korro Bio, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
What is Korro Bio, Inc.'s ROE?
Korro Bio, Inc.'s return on equity (ROE) is -110.7%. The historical average is -121.9%.
Is KRRO stock overvalued?
Based on historical data, Korro Bio, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Korro Bio, Inc.'s profit margins?
Korro Bio, Inc. has 33.0% gross margin and -1366.4% operating margin.